74 results on '"Arik, Zafer"'
Search Results
52. Inflammatory markers in metastatic breast cancer.
- Author
-
Sahin, Ugur, primary, Petekkaya, Hilbrahim, additional, Gecmez, Gizem, additional, Babacan, Taner, additional, C. Roach, Emir, additional, Sarici, Saim Furkan, additional, Arslan, Cagatay, additional, Arik, Zafer, additional, Aksoy, Sercan, additional, and Altundag, Kadri, additional
- Published
- 2013
- Full Text
- View/download PDF
53. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
- Author
-
Yazici, Ozan, primary, Aksoy, Sercan, additional, Ucar, Ozgul, additional, Özdemir, Nuriye, additional, Demir, Mevlut, additional, Sendur, Mehmet Ali Nahit, additional, Arik, Zafer, additional, Yaman, Sebnem, additional, Eren, Tulay, additional, Uncu, Dogan, additional, and Zengin, Nurullah, additional
- Published
- 2013
- Full Text
- View/download PDF
54. Is There an Association between Blood Group and Survival in Pancreatic Cancer?
- Author
-
Kos, F. Tugba, primary, Civelek, Burak, additional, Seker, M. Metin, additional, Arik, Zafer, additional, Aksoy, Sercan, additional, Uncu, Dogan, additional, Ozdemir, Nuriye, additional, and Zengin, Nurullah, additional
- Published
- 2012
- Full Text
- View/download PDF
55. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.
- Author
-
Sendur, Mehmet Ali Nahit, primary, Aksoy, Sercan, additional, Yaman, Sebnem, additional, Kos, Fahriye Tugba, additional, Arik, Zafer, additional, Civelek, Burak, additional, Özdemir, Nuriye, additional, Uncu, Dogan, additional, and Zengin, Nurullah, additional
- Published
- 2012
- Full Text
- View/download PDF
56. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.
- Author
-
Arik, Zafer, primary, Aksoy, Sercan, additional, Sendur, Mehmet Ali Nahit, additional, Yaman, Sebnem, additional, and Altundag, Kadri, additional
- Published
- 2012
- Full Text
- View/download PDF
57. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?
- Author
-
Yaman, Sebnem, primary, Aksoy, Sercan, additional, Sendur, Mehmet Ali Nahit, additional, Arik, Zafer, additional, Ozdemir, Nuriye, additional, Zengin, Nurullah, additional, and Altundag, Kadri, additional
- Published
- 2012
- Full Text
- View/download PDF
58. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use.
- Author
-
Aksoy, Sercan, primary, Sendur, Mehmet Ali Nahit, additional, Yaman, Sebnem, additional, Arik, Zafer, additional, Ozdemir, Nuriye, additional, Zengin, Nurullah, additional, and Altundag, Kadri, additional
- Published
- 2012
- Full Text
- View/download PDF
59. Can all beta blockers improve the breast cancer survival?
- Author
-
Sendur, Mehmet Ali Nahit, primary, Aksoy, Sercan, additional, Yaman, Sebnem, additional, Arik, Zafer, additional, and Altundag, Kadri, additional
- Published
- 2012
- Full Text
- View/download PDF
60. Dermatomyositis complicated with a soft tissue sarcoma
- Author
-
Şendur, Mehmet Ali Nahit, primary, Aksoy, Sercan, additional, Yaman, Şebnem, additional, Arik, Zafer, additional, Kilinç, Levent, additional, and Zengin, Nurullah, additional
- Published
- 2011
- Full Text
- View/download PDF
61. Isolated Testicular Metastasis of Gastric Cancer
- Author
-
Civelek, Burak, primary, Aksoy, Sercan, additional, Kös, Tugba, additional, Şeker, M. Metin, additional, Arik, Zafer, additional, Şendur, Mehmet Ali Nahit, additional, Yaman, Şebnem, additional, Cihan, Şener, additional, Özdemir, Nuriye Yildirim, additional, Uncu, Doğan, additional, Kulaçoglu, Sezer, additional, and Zengin, Nurullah, additional
- Published
- 2011
- Full Text
- View/download PDF
62. Molecular subtypes in patients with inflammatory breast cancer; A single center experience
- Author
-
Kertmen, Neyran, Babacan, Taner, Keskin, Ozge, Solak, Mustafa, Sarici, Furkan, Akin, Serkan, Arik, Zafer, Aslan, Alma, öztürk ateş, Aksoy, Sercan, Ozisik, Yavuz, and Altundag, Kadri
63. Retrospective Analysis of Gestational Trophoblastic Neoplasia: Single Center Experience.
- Author
-
SUNAR, Veli, KORKMAZ, Vakkas, ARIK, Zafer, OZDAL, Bulent, and ENGIN USTUN, Yaprak
- Subjects
- *
GESTATIONAL trophoblastic disease , *RETROSPECTIVE studies , *ACTINOMYCIN , *WOMEN'S health , *TREATMENT effectiveness - Abstract
This study aims to analyze the clinicopathologic characteristics and treatment outcomes of our patients with gestational trophoblastic neoplasia (GTN) and to present our real-life experience. A total of 32 patients with GTN diagnosed according to the FIGO 2002 criteria followed in Zekai Tahir Burak Women's Health Training and Research Hospital between 2011-2018 were included. Demographic features, treatment outcomes, and survival were analyzed retrospectively. The median follow up time was 32.1 (3.3-76.9) months. Of the 32 patients, 27 (84.4%) were defined as low-risk GTN (risk score < 7) and 5 (15.6%) were high-risk GTN (risk score ≥ 7) according to the FIGO risk score. Seventeen (62.9%) patients with low-risk GTN achieved complete remission (CR) with single agent MTX. CR rate was 60% (12/20) in patients receiving weekly MTX and 71.4% (5/7) in MTX-FA eight-day regimen (p= 0.590). Of the 9 MTX resistant patients, 8 (88.8%) achieved CR with second-line Actinomycin D (ActD). Three (60%) out of the five high-risk GTN patients acquired CR with first-line EMA-CO (etoposide, MTX, plus ActD alternating with cyclophosphamide and vincristine). In the follow-up period one patient (3.1%) had recurrent disease. By the data cut off date, all of the patients were alive and CR could not be achieved in one (3.1%) patient. All patients with low-risk GTN achieved CR with sequential therapies ultimately. Therefore, single agent MTX is a reasonable option in the initial treatment of low-risk GTN. Moreover, Actinomycin D is highly effective in patients with low-risk GTN who are resistant to MTX. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
64. Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer.
- Author
-
SUNAR, Veli, KORKMAZ, Vakkas, ASLAN, Koray, KOSE, Caner, SARICI, Furkan, ARIK, Zafer, and MEYDANLI, Mehmet Mutlu
- Subjects
- *
OVARIAN epithelial cancer , *PACLITAXEL , *OVERALL survival , *CARBOPLATIN , *SURVIVAL rate , *HYPERTHERMIC intraperitoneal chemotherapy , *INDUCED ovulation - Abstract
This study aims to compare efficacy of dose dense and conventionally dosed paclitaxel-carboplatin regimens in the first-line treatment of epithelial ovarian cancer (EOC). We evaluated the medical records of women with EOC followed in Zekai Tahir Burak Women's Health Training and Research Hospital between 2007-2019 retrospectively. The patients with Eastern Cooperative Oncology Group Performance Status of 0-1-2, and stages of IC-IV, without previous treatments, who had undergone primary cytoreductive surgery were included. All patients had received either dose dense paclitaxel-carboplatin (paclitaxel 80 mg/m2 given on days 1, 8, and 15 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) or conventionally dosed paclitaxel-carboplatin (paclitaxel 175 mg/m2 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) regimens in the first line treatment. Baseline clinicopathological features, progression-free survival, and overall survival were evaluated. This study included data of 133 patients. Forty patients had received dose dense regimen while 93 had conventionally dosed regimen. Median progression-free survival of the dose dense group [34.4 months (31.7 - 37.03)] was significantly longer than the conventional group [25.5 months (19.9-30.9)] [HR= 0. 55 (95% CI, 0.31 - 0.95), p= 0.03]. Median overall survival was 88.2 months (28.3 - 148.3) in the dose dense group and 76.5 months (63.3 - 89.7) in conventional group (p= 0.102). We have found improved progression-free survival in the first-line treatment of EOC with dose dense regimen compared to conventionally dosed regimen. Overall survival was longer in the dose dense group despite being not significant. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
65. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using 'Charlson Comorbidity Index' and 'Cumulative Illness Rating Scale'
- Author
-
Nuriye Ozdemir, Sercan Aksoy, Nurullah Zengin, Metin Seker, Zafer Arik, Burak Civelek, Ozan Yazici, F. Tuğba Köş, Dogan Uncu, [Kos, F. Tugba] Kahramanmaras Sutcu Imam Univ, Dept Med Oncol, Fac Med, TR-46000 Merkez, Kahramanmaras, Turkey -- [Yazici, Ozan -- Civelek, Burak -- Uncu, Dogan -- Ozdemir, Nuriye -- Zengin, Nurullah] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Seker, Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Arik, Zafer -- Aksoy, Sercan] Hacettepe Univ, Inst Oncol, Dept Med Oncol, Ankara, Turkey, and Aksoy, Sercan -- 0000-0003-4984-1049
- Subjects
Gerontology ,Adult ,medicine.medical_specialty ,Multivariate analysis ,Survival ,Turkey ,Digestive System Diseases ,Comorbidity ,Risk Assessment ,Severity of Illness Index ,Diabetes Complications ,Neoplasms, Multiple Primary ,Internal medicine ,Pancreatic cancer ,Severity of illness ,mental disorders ,medicine ,Humans ,Survival rate ,Pancreas ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Cancer ,Aged, 80 and over ,business.industry ,Proportional hazards model ,Incidence ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Confidence interval ,humanities ,Pancreatic Neoplasms ,Cumulative Illness Rating Scale ,Cardiovascular Diseases ,business ,Charlson Comorbidity Index - Abstract
WOS: 000330743400007, PubMed ID: 24249323, Effect of comorbidity on the treatments that patients receive is not clear, as healthy elderly patients and the elderly with less comorbid diseases are included in the studies. In the present study, the effect of comorbidity on the survival was evaluated using Charlson Comorbidity Index (CCI) and Cumulative Illness Rating Scale (CIRS). The general features and comorbid diseases of the pancreatic cancer patients were retrospectively screened from the patient files using the automated system. CCI and CIRS were used as the comorbidity indices. A total of 106 patients with pancreatic cancer were included in the study. The median overall survival rate was 9.0 [95 % confidence interval (CI): 6.7-11.3] months. The median overall survival rate was found as 9.4 (95 % CI: 6.7-12.1) months in the patients whose CCI score was a parts per thousand currency signaEuro parts per thousand 2 and was found as 6.2 (95 % CI: 4.0-8.3) months in the patients with CCI scores a parts per thousand yenaEuro parts per thousand 3 (p = 0.05). The median overall survival rate was calculated as 9.8 (95 % CI: 6.3-13.4) months in the patients with CIRS scores a parts per thousand currency signaEuro parts per thousand 2 and was calculated as 8.3 (95 % CI: 6.0-10.6) months in the patients with CIRS scores a parts per thousand yenaEuro parts per thousand 3 (p = 0.51). When surgery, radiotherapy, grading, and CCI score were evaluated using multivariate analysis, it was observed that only the treatment modality had a significant effect on the survival rate. The results on the use of comorbidity indices are contradictory for the cancers with lower survival rates such as pancreatic cancer. New prognostic scales might be developed for this patient group by considering the side effects of chemotherapy.
- Published
- 2014
66. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group.
- Author
-
Akyildiz A, Gultekin M, Yigit E, Demir E, Ismayilov R, Ahmed M, Buyukkor M, Yildirim HC, Yildirim N, Ucar G, Algin E, Ozturk AE, Akbas S, Selcukbiricik F, Orman S, Turan N, Yilmaz M, Colak R, Engin EO, Majidova N, Bayoglu IV, Beyaz H, Ates O, Ibıs K, Ergen SA, Yuce Sari S, Tezcan Y, Yildiz F, and Arik Z
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Adult, Aged, Turkey epidemiology, Antineoplastic Agents administration & dosage, Young Adult, Aged, 80 and over, Neoplasm Staging, Uterine Cervical Neoplasms therapy, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms drug therapy, Cisplatin administration & dosage, Chemoradiotherapy methods
- Abstract
Objective: To investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy., Methods: A retrospective analysis was conducted on 654 patients with stage IB3-IVA disease treated with definitive chemoradiotherapy. Radiotherapy was applied as external beam pelvic with or without para-aortic radiotherapy and brachytherapy. Concomitant chemotherapy was in the form of weekly or 3 weekly cisplatin. Data on demographics, treatment protocols, cumulative cisplatin dose, adverse effects, and survival outcomes were collected. Statistical analyses, including univariate and multivariate Cox regression models, were used to assess factors influencing progression free survival and overall survival., Results: The median cumulative cisplatin dose was 210 mg (range 40-320), and ≥200 mg in 503 (76.9%) patients. Median follow-up was 35 months (range 1-150). The 5 year progression free survival and overall survival rates were 66.9% and 77.1%, respectively. Multivariate analysis identified poor performance status, non-squamous cell histology, presence of lymph node metastases, and hemoglobin <10 g/dL before chemoradiotherapy as poor prognostic factors for both progression free survival and overall survival in the whole group. When stage III cases were evaluated separately, the cumulative cisplatin dose <200 mg was found to be a significant poor prognostic factor in overall survival (hazard ratio 1.79, 95% confidence interval 1.1 to 3.0, p=0.031)., Conclusion: Our study showed that a cumulative cisplatin dose >200 mg, particularly in patients with lymph node metastases, significantly improved overall survival. Factors such as anemia, toxicity related challenges, and comorbidities were identified as critical considerations in treatment planning. These findings emphasize the balance between maximizing therapeutic efficacy and managing toxicity, guiding personalized treatment approaches for locally advanced cervical cancer., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
67. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab.
- Author
-
Yildirim HC, Anik H, Ozdemir DA, Ismayilov R, Akyildiz A, Cayiroz K, Ceyhan F, Kavruk O, Guven DC, Ates O, Usubutun A, and Arik Z
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Aged, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Neoplasm Metastasis, Prognosis, Progression-Free Survival, Bevacizumab therapeutic use, Bevacizumab pharmacology, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms metabolism, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell metabolism, Hypoxia-Inducible Factor 1, alpha Subunit metabolism
- Abstract
This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor (VEGF)-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy.
- Published
- 2024
- Full Text
- View/download PDF
68. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia.
- Author
-
Korkmaz V, Sunar V, Akar S, Alinca CM, Arik Z, Boran N, Ozdal B, and Ustun YE
- Subjects
- Adult, Female, Humans, Leucovorin adverse effects, Methotrexate, Middle Aged, Pregnancy, Retrospective Studies, Gestational Trophoblastic Disease chemically induced, Gestational Trophoblastic Disease drug therapy, Gestational Trophoblastic Disease pathology, Lung Neoplasms drug therapy
- Abstract
Aim: We aimed to compare weekly methotrexate (MTX) regimen and methotrexate-folinic acid (MTX-FA) 8-day regimen in the first line treatment of low-risk gestational trophoblastic neoplasia (GTN)., Methods: The study included 73 patients with low-risk GTN according to FIGO risk score (FIGO risk score < 7). All patients received either weekly MTX (30-50 mg/m
2 intramuscular weekly) or MTX-FA 8-day (MTX 1 mg/kg IV on day 1, 3, 5, and 7, FA 15 mg orally on day 2, 4, 6, and 8 given 24 h after each MTX dose, every 14 days) regimens in the first-line treatment of low-risk GTN. The baseline clinicopathological characteristics and treatment outcomes were analyzed retrospectively., Results: The median age of all patients was 29 (18-51) years, and the median FIGO risk score was 3 (1-6). Of the patients recruited, 53 received MTX-FA 8-day, and 20 had MTX weekly regimens. There was a significant difference between the two groups with respect to FIGO risk scores (3 [1-6] vs. 2 [1-5], p = 0.023, MTX-FA 8-day vs. MTX weekly, respectively). The complete response rate was significantly higher in MTX-FA 8-day group compared to MTX weekly group (83% [44/53] vs. 60% [12/20] p = 0.038). In univariate and multivariate regression analyses, only presence of lung metastasis was found to be an independent risk factor for treatment resistance (OR: 3.959, 95% CI 1.105-14.179, p = 0.035)., Conclusion: MTX-FA 8-day regimen is more effective than weekly MTX regimen in the first line treatment of low-risk GTN including patients even with higher FIGO risk scores. Treatment resistance may develop especially in patients with lung metastasis., (© 2021 John Wiley & Sons Australia, Ltd.)- Published
- 2022
- Full Text
- View/download PDF
69. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
- Author
-
Sunar V, Korkmaz V, Topcu V, Cavdarli B, Arik Z, Ozdal B, and Ustun YE
- Subjects
- Breast Neoplasms, Cross-Sectional Studies, Female, Genetic Predisposition to Disease, Germ Cells, Humans, Mutation, BRCA1 Protein genetics, BRCA2 Protein genetics, Carcinoma, Ovarian Epithelial genetics, Germ-Line Mutation, Ovarian Neoplasms genetics
- Abstract
Aim: This study aims to determine the frequency of germline BRCA 1/2 mutations in Turkish women with epithelial ovarian cancer (EOC) and evaluate its relationship with clinicopathological characteristics., Methods: In this cross-sectional study, all women with recently diagnosed EOC presenting to Zekai Tahir Burak Women's Health Training and Research Hospital Medical Oncology Clinic between 2016 and 2019 were referred for BRCA testing. Peripheral blood samples were obtained from 76 patients applying to Medical Genetics and BRCA1/2 genes were sequenced using next-generation sequencing. The American College of Medical Genetics and Genomics 2015 criteria were followed for classification of genetic variants., Results: Twenty-four women (31.6%) had pathogenic germline BRCA1/2 mutations. Of these, 17 patients (22.4%) harbored germline BRCA1 mutations and 7 (9.2%) had BRCA2 mutations. When we compared the patients with and without BRCA mutations, there was significant difference in terms of family history (41.7% vs 9.6%, respectively, P = .001). Among all patients, 15 (19.7%) had history of breast or ovarian cancer in first- or second-degree relatives. Germline BRCA1/2 mutations were detected in 66.7% of patients with family history, while these mutations were found in 22.9% of patients without family history (P = .001)., Conclusion: In this sample 31.6% of Turkish women with EOC harbored germline BRCA1/2 mutations, which seems higher compared to other ethnic groups except for the Ashkenazi Jews population. All women with EOC should be referred for BRCA testing regardless of family history, age at diagnosis, and histological subtype., (© 2021 John Wiley & Sons Australia, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
70. Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe).
- Author
-
Gultekin M, Ak S, Ayhan A, Strojna A, Pletnev A, Fagotti A, Perrone AM, Erzeneoglu BE, Temiz BE, Lemley B, Soyak B, Hughes C, Cibula D, Haidopoulos D, Brennan D, Cola E, van der Steen-Banasik E, Urkmez E, Akilli H, Zapardiel I, Tóth I, Sehouli J, Zalewski K, Bahremand K, Chiva L, Mirza MR, Papageorgiou M, Zoltan N, Adámková P, Morice P, Garrido-Mallach S, Akgor U, Theodoulidis V, Arik Z, Steffensen KD, and Fotopoulou C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anxiety psychology, COVID-19 epidemiology, COVID-19 virology, Depression psychology, Europe, Fear psychology, Female, Humans, Middle Aged, Pandemics, SARS-CoV-2 physiology, Young Adult, COVID-19 prevention & control, Genital Neoplasms, Female psychology, Genital Neoplasms, Female therapy, SARS-CoV-2 isolation & purification, Surveys and Questionnaires
- Abstract
Background: The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications., Methods: A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations., Findings: We collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety., Interpretation: Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education., (© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
71. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
- Author
-
Sunar V, Korkmaz V, Akin S, Can Guven D, Arik Z, Ates O, Yilmaz M, Mutlu Meydanli M, and Oksuzoglu B
- Subjects
- Adult, Aged, Female, Humans, Indazoles, Middle Aged, Neoplasm Metastasis, Pyrimidines pharmacology, Sarcoma pathology, Sulfonamides pharmacology, Uterine Neoplasms pathology, Pyrimidines therapeutic use, Sarcoma drug therapy, Sulfonamides therapeutic use, Uterine Neoplasms drug therapy
- Abstract
Purpose: Uterine sarcoma accounts for 3-9% of uterine malignant tumors and has poor prognosis. Pazopanib is an oral multi-kinase inhibitor and the only tyrosine kinase inhibitor which has been approved for metastatic soft tissue sarcoma. In the present study we aimed to evaluate the efficacy of pazopanib in metastatic uterine sarcoma., Methods: The data of 28 metastatic uterine sarcoma patients receiving pazopanib therapy, who were followed in four oncology centers in Ankara, Turkey between May 2013 and June 2018, were retrospectively analyzed. Patients over 18 years, ECOG performance status ≤ 2, receiving at least one line of chemotherapy for metastatic disease, measurable disease at diagnosis, and histologically proven uterine high grade sarcoma were the inclusion criteria. Progression-free survival (PFS), overall survival (OS), and response rates to pazopanib were retrospectively evaluated., Results: The median age was 53 years (range, 26-76). The majority of the patients had uterine leiomyosarcoma (LMS) (n=25, 89.3%), 2 (7.1%) had undifferentiated uterine sarcoma (UUS), and 1(3.6%) had high grade endometrial stromal sarcoma (ESS). The most common site of metastasis was lung (n: 21, 75%). The median time for pazopanib therapy was 5 months (0.6-28.3). In 22 patients (78.5%), pazopanib was discontinued due to disease progression, while 2 patients (7.1%) quitted therapy owing to toxicity. Partial response was achieved in 4 patients (14.3%), while 17 (60.7%) had stable disease. Median PFS was 5.2 months (95% CI 2.8-7.5) and median OS was 11.4 months (95% CI 3.4-19.5)., Conclusion: In the present study aiming to assess the real-life outcome of pazopanib-treated patients, we found that pazopanib is efficient in metastatic uterine sarcoma, and our results correspond to the literature.
- Published
- 2019
72. Which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats.
- Author
-
Kertmen N, Aksoy S, Uner A, Sargon M, Ozkayar O, Keskin O, Babacan T, Sarici F, Sendur MA, Arik Z, Akin S, and Altundag K
- Subjects
- Animals, Microscopy, Electron, Transmission, Mitochondria, Heart drug effects, Mitochondria, Heart ultrastructure, Rats, Rats, Wistar, Trastuzumab, Antibodies, Monoclonal, Humanized toxicity, Doxorubicin toxicity, Heart drug effects
- Abstract
Background/aim: Two effective cytotoxic agents, doxorubicin and trastuzumab, are associated with potentially life-threatening cardiotoxicity. The present study was designed to investigate cardiotoxicity aggravated by the timing of administration of trastuzumab and doxorubicin in rats., Materials and Methods: Twenty-four rats were randomly assigned to one of four groups. These received one of the following treatment drug regimens administered via intraperitoneal injection: (i) 0.9% saline control (n=6); (ii) doxorubicin (5 mg/kg) on day 1 then trastuzumab 10 mg/kg on day 15 (n=6); (iii) trastuzumab 10 mg/ kg on day 1 then doxorubicin (5 mg/kg) on day 15 (n=6) or (iv) doxorubicin (5 mg/kg) on day 1 and trastuzumab 10 mg/ kg on day 1 (n=6). On the 30th day, the hearts were processed for pathological analysis by electron microscopy., Results: Electron microscopy revealed an ultrastructurally normal heart tissue in the control group. At electron microscopic examination of the tissue samples in the second and fourth group, a mild degree of dilation was observed in the peri-nuclear cisternae of some heart muscle cells. In the third group, pathological changes were detected in mitochondria. These exhibited prominent cristae, which also showed a mild degree of ultrastructural pathology in mitochondria., Conclusion: Based on electron microscopy findings, sequential administration of anthracycline first, followed by trastuzumab is safer in terms of cardiotoxicity, while the most toxic schedule for the rat heart was trastuzumab first, followed by anthracycline., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
73. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature.
- Author
-
Durdu Keskin O, Kertmen N, Karakas Y, Babacan T, Arik Z, Altundag K, and Gullu I
- Subjects
- Bone Neoplasms therapy, Brain Neoplasms therapy, Female, Humans, Liver Neoplasms therapy, Lung Neoplasms therapy, Middle Aged, Neoplasm Staging, Time Factors, Treatment Outcome, Bone Neoplasms secondary, Brain Neoplasms secondary, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma, Ductal, Breast secondary, Carcinoma, Ductal, Breast surgery, Liver Neoplasms secondary, Lung Neoplasms secondary, Mastectomy, Modified Radical
- Published
- 2015
74. Molecular subtypes in patients with inflammatory breast cancer; a single center experience.
- Author
-
Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akin S, Arik Z, Aslan A, Ates O, Aksoy S, Ozisik Y, and Altundag K
- Subjects
- Female, Humans, Immunohistochemistry, Inflammatory Breast Neoplasms diagnostic imaging, Inflammatory Breast Neoplasms mortality, Inflammatory Breast Neoplasms secondary, Inflammatory Breast Neoplasms therapy, Kaplan-Meier Estimate, Mammography, Neoplasm Staging, Predictive Value of Tests, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Triple Negative Breast Neoplasms diagnostic imaging, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms secondary, Triple Negative Breast Neoplasms therapy, Turkey, Biomarkers, Tumor analysis, Inflammatory Breast Neoplasms chemistry, Triple Negative Breast Neoplasms chemistry
- Abstract
Purpose: The purpose of this study was to investigate the frequency and prognosis of inflammatory breast cancer (IBC) according to molecular subtypes., Methods: Demographic data were examined for 78 patients diagnosed with IBC among breast cancer patients monitored in our clinic. Patients were staged according to the 2010 AJCC guidelines. Physical examination and radiographic findings classified on the basis of Response Evaluation Criteria in Solid Tumors (RECIST) guidelines were employed in the evaluation of clinical response to systemic therapy. Subtype analysis was performed in patients with IBC and subtypes were compared. Patients were divided on the basis of metastatic or non metastatic status and survival analysis was performed on the basis of molecular subtypes., Results: Distribution analysis of molecular subtypes revealed a lower incidence of luminal A and a higher incidence of both HER 2 (+) and triple negative breast cancer in IBC. Molecular subtypes had no effect on survival in the non metastatic (p=0.61) and metastatic patient group (p=0.08)., Conclusion: This study showed that IBC frequency is higher in HER2 overexpressing and triple negative subtypes. No survival differences were noticed in relation to molecular subtypes in IBC patients.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.